Purva Sharma, MD
Hematology & Oncology · Warwick, RINPI 1609227370
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $883 of the $1,094 with a category attached, or 80.7%. It is spread thinly across 19 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $465, more than ten times the $11 reported in 2021.
Across 37 payments — averaging $29.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$257
- Amgen$199
- Novartis$98
- Gilead$62
- Pfizer$57
- Boehringer Ingelheim$57
- plus $363 from 13 others
What the payments were for
- Food & beverage$88381%
- Education$21119%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $257 |
| Amgen | 2 | $199 |
| Novartis | 3 | $98 |
| Gilead | 3 | $62 |
| Pfizer | 3 | $57 |
| Boehringer Ingelheim | 3 | $57 |
| Merck | 3 | $55 |
| AstraZeneca | 2 | $49 |
| Sanofi | 1 | $36 |
| ADC Therapeutics America, Inc. | 2 | $34 |
| Array Biopharma Inc | 2 | $33 |
| Bristol Myers Squibb | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavneos$111
How this compares
$1,094 in reported general payments places this provider in the 60th percentile of 68 hematology & oncology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 14 | $196,772 |
| XtandiEnzalutamide | 13 | $166,146 |
| EliquisApixaban | 44 | $31,150 |
| Abiraterone Acetate | 20 | $19,157 |
| CreonLipase/Protease/Amylase | 17 | $10,404 |
| Dexamethasone | 47 | $462 |
| Oxycodone Hcl | 58 | $442 |
| Hydroxyurea | 23 | $433 |
| Ondansetron OdtOndansetron | 24 | $422 |
| Letrozole | 19 | $363 |
| Prochlorperazine Maleate | 35 | $360 |
| Ondansetron Hcl | 30 | $230 |
| Gabapentin | 20 | $206 |
| Omeprazole | 11 | $161 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $32 | $196,77214 claims |
| PfizerEliquis | $57 | $31,15044 claims |
| AbbVieCreon | $15 | $10,40417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 68 hematology & oncology providers in Rhode Island.
Other hematology & oncology in Warwick
- Gerald ColvinWakefield$233K
- William SikovProvidence$156K
- Ritesh RathoreProvidence$148K
- Anthony MegaProvidence$65K
- Adam OlszewskiProvidence$63K
- Ahmed NadeemWoonsocket$53K
- Hina KhanProvidence$34K
- Peter BarthProvidence$29K
- Thomas OllilaProvidence$19K
- John ReaganProvidence$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.